Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings results on February 19, 2026 that fell short of analyst expectations. The Healthcare company reported earnings…
Madrigal Pharmaceuticals (NASDAQ:MDGL) reported quarterly earnings results on February 19, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-2.57, missing the consensus estimate of $-0.52 by $2.05 per share. Revenue came in at $321.1M, beating the estimate of $313.0M.
Madrigal Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $434.11 with a market capitalization of $12.7B.
Current market data
NASDAQ · MDGL
$540.03
Up: +$6.27 · +1.17%
Live quote updated
Our Markets Team monitors market data, SEC filings, analyst actions, earnings releases, and corporate announcements to produce timely updates for investors.
Keep reading
sec_filing ·
analyst ·
price ·
analyst ·
